Key result
Exposure to anthracycline doses ≥250 mg/m2 increased the odds of cardiomyopathy in adult survivors of childhood cancer compared to no exposure (OR 2.7; 95% CI 1.1-6.9).
Population
1853 adult survivors of childhood cancer, aged 18 years or older, who received cancer-related cardiotoxic…
Design
Cross-sectional
Follow-up
at least 10 years
Authors
Loading...
Anthracycline doses ≥250 mg/m² associated with cardiomyopathy; hypothesis-generating for screening thresholds, needs prospective validation in survivors.
Cross-Sectional (n=1,853)
No
Odds Ratio: 2.7 (95% CI 1.1–6.9)
Adult survivors of childhood cancer exposed to cardiotoxic therapy have a high prevalence of asymptomatic, subclinical cardiac disease, highlighting the need for routine cardiovascular screening.
Mulrooney et al. (2016) conducted a cross-sectional in Adult survivors of childhood cancer (n=1,853). Anthracycline chemotherapy (≥250 mg/m2) vs. No exposure was evaluated on Cardiomyopathy (OR 2.7, 95% CI 1.1 to 6.9). Exposure to anthracycline doses ≥250 mg/m2 increased the odds of cardiomyopathy in adult survivors of childhood cancer compared to no exposure (OR 2.7; 95% CI 1.1-6.9).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: